Trial Profile
A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Subjects With Controlled Blood Pressure
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Jan 2023
Price :
$35
*
At a glance
- Drugs IONIS AGT LRx (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Ionis Pharmaceuticals
- 17 May 2021 Primary endpoint (Percent change in plasma angiotensinogen from Baseline to Study Day 43 (Week 7) compared to placebo) has been met, as per results presented at the 70th Annual Scientific Session of the American College of Cardiology.
- 17 May 2021 Results of NCT03101878 and NCT03714776, presented at the 70th Annual Scientific Session of the American College of Cardiology.
- 11 Feb 2020 Status changed from active, no longer recruiting to completed.